Testing effectiveness (Phase 2)Active Not RecruitingNCT05270668
What this trial is testing
Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007)
Who this might be right for
Diffuse Cutaneous Systemic SclerosisInterstitial Lung Disease
Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) 154